Big Guy v. Little Guy
Executive Summary
It started off as a perfect relationship: diagnostic giant Boehringer Mannheim and tiny Igen would jointly develop an immunoassay analyzer based on Igen's impressive new electrochemiluminesence (ECL) technology. Now the two companies find themselves in court, with Igen charging, among other things, that BMC didn't calculate royalties fairly and BMC seeking to retain rights to sell the ECL analyzer.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.